Gimmune GmbH was established in 2008. We developed and patented novel anti-cancer/viral compounds, anti-glycan antibodies, and nano-devices

Products

Nano-electrophoresis and nano in micro arrays for single-cell analysis

Novel anti-cancer and anti-viral compounds

Anti-glyconectin monoclonal antibodies

R&D Activities

Monoclonal antibodies against carcino-embryonal markers

NK cell proliferation

Glycocalyx and Glyconectin structure and function

Collaborations

9 Universities

1 biomed company

Publications & Patents

We have exclusive rights to produce, sell and distribute above mentioned  three classes of custom tailored products

Gimmune GmbH, Baarerstrasse 12, 6300 Zug, Switzerland

gimmune@gimmune.com